Loading publications…
The last 5 uploaded publications
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T
James Buteau, Louise Kostos, Ramin Alipour, Price Jackson, Lachlan McInstosh, Brittany Emmerson, Mohammad B. Haskali, Jing Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Benjamin J. Blyth, Luc Furic, Katie L. Owen, Shahneen Sandhu, Declan G. Murphy, Arun Azad, Michael S. Hofman (2024). Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T. , 65(8), DOI: https://doi.org/10.2967/jnumed.124.267650.
Article62 days agoAbstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
Heidi Fettke, Louise Kostos, James Buteau, Jason A. Steen, Elizabeth Medhurst, Mo B. Haskali, Declan G. Murphy, Maria Docanto, Patricia Bukczynska, Nicole Ng, Shahneen Sandhu, Siavash Foroughi, Luc Furic, Tú Nguyen‐Dumont, Michael S. Hofman, Arun Azad (2023). Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). , 83(7_Supplement), DOI: https://doi.org/10.1158/1538-7445.am2023-5614.
Article62 days ago